notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title Respiratory syncytial virus (RSV) ワクチン開発にいたるまで
Subtitle 特集 予防接種の話題と課題
Authors 中山哲夫
Authors (kana)
Organization 北里大学 大村智記念研究所 ウイルス感染制御
Journal 東京小児科医会報
Volume 42
Number 2
Page 47-54
Year/Month 2024 / 3
Article 報告
Publisher 東京小児科医会
Abstract 「要約」 Respiratory syncytial virus (RSV)は毎年流行を繰り返し2歳までにほぼ全員が罹患し特に基礎疾患を持つ乳幼児, 新生児では重症化し入院する. 世界中で毎年約340万人が入院し十数万人が亡くなる重要なウイルス感染症である. 1960年代にホルマリン不活化ワクチンが開発されたがワクチン接種後にRSVに感染すると重症化し死亡する例がみられワクチン開発にとって大きなハードルとなった. 高い中和活性をもつF蛋白の立体構造, 免疫応答が解明され新規ワクチン開発への挑戦が始まった. 新生児を守るための妊婦へのワクチン, さらに高齢者を対象としたワクチンが承認されワクチン開発までの経緯を概説する.
Practice 臨床医学：内科系
Keywords
  • 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
download全文ダウンロード(6.57MB)

参考文献

  • 1) Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019:a systematic analysis. Lancet 2022;399:2047-2064. doi.org/10.1016/S0140-6736(22)00478-0
  • 2) Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. New Engl J Med 2005;352:1749-1759.
    pubmed
  • 3) 伊藤尚志. RSウイルス感染症の疫学. 臨床とウイルス 2023;51:81-85.
    Medical*Online
  • 4) Anderson LJ, Dormitzer PR, Nokes DJ, et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013;31S:B209-B215. Doi.10.1016/j.vaccine.2012.11.106
  • 5) Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection and disease pathogenesis to guide RSV vaccine development. Front Immunol 2019;10:1675. doi.org/10.3389/fimmu.2019.01675
残りの28件を表示する
  • 6) Johnson SM, McNally BA, Ioannidis I, et al. Respiratory syncytial virus uses CXCR1 as a receptor on primary human airway epithelial cultures. PLOS Path 2015;11:e1005318. doi.10.1371/journal.ppat.1005318.
  • 7) Tayyari F, Marchant D, et al:Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nature Med 17:1132-1135, 2011
    pubmed
  • 8) Hovanessian AG, Soundaramourty C, El Khoiry D, et al. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization, PLoS One 2010;5:e15787. doi:10.1371/journal.pone.0015787
  • 9) Crank MC, Ruckwardt TJ, Chen M, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 2019;365:505-509. doi:10.1126/science.aav9033
  • 10) Esposito S, Abu-Raya B, Bonanni P, et al. Coadministration of anti-viral monoclonal antibodies with pediatric vaccines and implications for Nirsevimab use:a white paper. Front Immunol 2021;12:708939. doi.org/10.3389/fimmu.2021.708939.
  • 11) Domachowske JB, Khan AA, Esser MT, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J 2018;37:886-92. doi:10.1097/INF.0000000000001916
  • 12) Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-421. doi:10.1093/oxfordjournals.aje.a120954.
  • 13) Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988;26:1595-1597. doi.org/10.1128/jcm26.8.1595-1597.1988
  • 14) Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 2007;39:225-239. Doi.10.1007/s12026-007-0071-6
  • 15) Ruckwardt TJ, Morabito KM, Graham BS. Immunological lessons from respiratory syncytial virus vaccine development. Immunity 2019;51:429-442. doi:10.1016/j.immuni.2019.08.007.
  • 16) Sawada A, Nakayama T. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus. Microbiol Immunol 2016;60:234-242. doi:10.1111/1348-0421.12365
  • 17) Shaw CA, Ciarlet M, Cooper BW, et al. The path to an RSV vaccine. 2013;3:332-342. doi.org/10.1016/j.coviro.2013.05.003
  • 18) Simoes EAF, Center KJ, Tita ATN, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med 2022;386:1615-1626. doi:10.1056/NEJMoa2106062
  • 19) Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. New Engl J Med 2023;388:1451-1464. doi:10.1056/NEJMoa2216480
  • 20) Leroux-Roels I, Davis MG, Steenackers K, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults:phase 1 / 2 randomized clinical trial. J Infect Dis 2023;227:761-772. doi.org/10.1093/infdis/jiac327
  • 21) Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. New Engl J Med 2023;388:595-608. doi:10.1056/NEJMoa2209604.
  • 22) Walsh EE, Falsey AR, Scott DA, et al. A randomized phase 1 / 2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis 2022;225:1357-1366.
    pubmed
  • 23) Walsh EE, Perez Marc G, Zareba AM, Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. New Engl J Med 2023;388:1465-1477. doi:10.1056/NEJMoa2213836.
  • 24) Topalidou X, Kalergis AM, Papazisis G. Respiratory syncytial virus vaccines:a review of the candidates and the approved vaccines. Pathogens 2023;12:1259. doi.org/0.3390/pathogens12101259
  • 25) Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults. https://investors.icosavax.com/news-releases/news-release-details/icosavax-announces-positive-topline-interim-phase-1-results (2023, 12 10 accessed)
  • 26) Nussbaum J, Cao X, Raikar Ra, et al. Evaluation of a stabilized RSV pre-fusion F mRNA vaccine:Preclinical studies and Phase 1 clinical testing in healthy adults. Vaccinen2023;41:6488-6501. doi:10.1016/j.vaccine.2023.05.062. Epub 2023 Sep 29. 31
  • 27) Wilson E, Goswami J, Baqui AH, et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med 2023;389:2233-2244. DOI:10.1056/NEJMoa2307079
  • 28) Jin H, Zhou H, Cheng X, et al. Recombinant Respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 273:210-218, 2000. doi:10.1006/viro.2000.0393.
  • 29) Verdijk P, van der Plas JL, van Brummelen EMJ, et al. First-in-human administration of a live-attenuated RSV vaccine lacking the G-Protein assessing safety, tolerability, shedding and immunogenicity:a randomized controlled trial. Vaccine 2020, 38, 6088-6095. doi.org/10.1016/j.vaccine.2020.07.029
  • 30) Cunningham CK, Karron RA, Muresan P, et al. Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-seronegative children. J Infect Dis 2022;226:2069-2078.
  • 31) Jordan E, Kabir G, Schultz S, et al. Reduced respiratory syncytial virus load, symptoms, and infections:a human challenge trial of MVA-BN-RSV vaccine. J Infect Dis 2023;228:999-1011. doi.org/10.1093/infdis/jiad108
  • 32) Falsey AR, Williams K, Gymnopoulou Efi, et al. Efficacy and Safety of an Ad26. RSV. preF-RSV preF Protein Vaccine in Older Adults. New Engl J Med 2023;388:609-620. doi:10.1056/NEJMoa2207566.
  • 33) Diez-Domingo J, Saez-Llorens X, Rodriguez-Weber MA, et al. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age. J Infect Dis 2023;227:1293-1302. doi.org/10.1093/infdis/jiac481
はじめての方へ
個人／法人会員登録のご案内